Santen launches Verkazia in Europe to treat VKC in children

Santen U.K. Ltd. announced the launch of Verkazia eye drops in Europe for the treatment of severe vernal keratoconjunctivitis in adolescents and children at least 4 years old.
Verkazia (0.1% cyclosporine), an immunomodulator that targets the underlying cause of the inflammation at the surface of the eye, controls the allergic response and inflammation.
It has been shown to relieve the most common symptoms of VKC over a 12-month period, according to a press release from Santen.
The recommended dose will be one drop administered four times a day in each (Read more...)

Full Story →